US/UK/Canada

Share

Pick a time period -
Tags ( Active)

LSE and ESC announce the launch of an executive-style Masters Programme

The MSc in Health Economics, Outcomes and Management in Cardiovascular Sciences aims to equip cardiovascular specialists with health management, economics, research and policy skillsBrussels/London, Thursday 24 July 2014. LSE Health and the European Heart Academy (EHA) of the European Society of Cardiology (ESC) are pleased to announce the launch of a new, executive-style MSc aimed at professionals working in the field of cardiovascular sciences. The MSc in Health Economics, Outcomes and Management in Cardiovascular Sciences aims to equip cardiovascular specialists with the health

EHRA White Book 2014 highlights growing use of complex therapies for heart rhythm abnormalities in Europe

Current status of arrhythmia treatment in European countriesFor immediate release Nice, France, 17 June 2014. The EHRA (European Heart Rhythm Association) White Book 2014 will be officially launched at the CARDIOSTIM EHRA EUROPACE 2014 congress which starts tomorrow in Nice, France. The White Book reports on the current status of arrhythmia treatment in 49 of the 56 European Society of Cardiology (ESC) member countries for the year 2013. The new White Book is published in electronic format only and will be distributed on a USB stick as well as being available on the EHRA website. As a

Prevent premature deaths from heart failure, urges the Heart Failure Association

A call for policy change with the power to drive improvements that save livesEmbargoed until 14h30 CEST on 16 May 2014 Prevent premature deaths from heart failure, urges the Heart Failure Association A call for policy change with the power to drive improvements that save lives Athens, 16 May 2014. The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) is calling for global policy change relating to heart failure. An international white paper, Heart failure: preventing disease and death worldwide, will be presented at an endorsement event on 16 May 2014 in

One-quarter of high risk patients denied anticoagulation after AF ablation

Very good long-term results for Atrial Fibrillation catheter ablation across EuropeFor immediate release Sophia Antipolis, 18 February 2014: One-quarter of high risk patients do not receive anticoagulants after ablation of atrial fibrillation (AF), according to the latest survey of European practice. The EORP Atrial Fibrillation Ablation Pilot Study, conducted by the European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC), reveals that 65% of patients were taking anticoagulants one year after ablation of AF.1 But up to 25% of patients at high risk of

New AF classification by ECG will help GPs deliver personalised treatment

Despite the availability of cardioversion, ablation and medications to treat AF, outcomes are often poor because it is unclear which patients will benefit most.Topics: Atrial fibrillation Sophia Antipolis, 20 December 2013: A new classification of atrial fibrillation (AF) by electrocardiogram (ECG) is set to be developed by European experts to aid personalised management of this devastating condition. The decision to establish a classification comes after the first European conference on standardising ECG analysis of AF was held earlier this month in Lugano, Switzerland. The meeting

World’s largest imaging congress reveals latest techniques in heart failure

EuroEcho-Imaging 2013 showcases new imaging research for heart failure diagnosis and treatment11-14 December 2013 in Istanbul, Turkey Sophia Antipolis, 12 November 2013. The latest science on the role of imaging in diagnosing and treating heart failure will be presented at EuroEcho-Imaging 2013, the official annual meeting of the European Association of Cardiovascular Imaging (EACVI), a registered branch of the European Society of Cardiology (ESC). It takes place during 11-14 December in Istanbul, Turkey, at the Istanbul Lutfi Kirdar Convention & Exhibition Centre (ICEC). EuroEcho-

Get ready for the latest innovations in acute cardiac care

Acute Cardiac Care Congress 2013, from 12 to14 October 2013 in Madrid, SpainSophia Antipolis, 16 September 2013. The Acute Cardiac Care Congress 2013 is the event of the year for the latest innovations in the field. The Congress is the annual meeting of the Acute Cardiovascular Care Association (ACCA) of the European Society of Cardiology (ESC). It takes place during 12-14 October in Madrid, Spain, at the Hotel Auditorium. Cutting edge science and treatments in acute cardiovascular care will be presented in more than 300 abstracts by scientists from across the globe and generate a rich

Best of ESC Congress 2013

· We must not forget that despite advances, cardiovascular disease remains the number one killer in Europe · Clinical trials with immediate implications on clinical practice and future guidelines presented at ESC Congress 2013 · Huge inequalities in health care persist, ESC will continue efforts to lobby for best treatments to be equally accessible to all European patientsAmsterdam, 4 September 2013: Close to thirty thousand delegates converged from all over the world, to the ESC Congress 2013 in Amsterdam, The Netherlands, this week. Cardiologists came to hear first-hand about the

Hot Line III - Late Breaking Trials on Risk factors and Diabetes

Dear Press member,Please find here the links (live at 08:00 CEST) to press releases from the ESC Press Conference on ESC Congress 2013: Hot Line III - Late Breaking Trials on Risk factors and Diabetes: · http://www.escardio.org/about/press/press-releases/esc13-amsterdam/Pages/hotline-three-pure.aspx · http://www.escardio.org/about/press/press-releases/esc13-amsterdam/Pages/hotline-three-examine.aspx · http://www.escardio.org/about/press/press-releases/esc13-amsterdam/Pages/hotline-three-savor-timi-53.aspx · http://www.escardio.org/about/press/press-releases/esc13-amsterdam/

ESC Congress 2013: Record number of Hot Line submissions

Four Hot Line sessions this yearSophia Antipolis, 08 August 2013: ESC Congress 2013 has received a record number of Hot Line submissions and nearly 10,500 abstract submissions. The world’s premier cardiovascular congress promises to unveil the latest in international cardiovascular science and will be held in Amsterdam, the Netherlands, from 31 August to 4 September 2013. The Scientific Programme is available here: http://spo.escardio.org/default.aspx?eevtid=60 Journalists can anticipate a packed press programme, with four Hot Lines press conferences and seven additional press

Consensus statement on paediatric arrhythmias released by ESC and AEPC

First European statement concerning the diagnosis and management of paediatric arrhythmias. It is also the first joint document between EHRA and the AEPC.Sophia Antipolis, 18 July 2013: A joint consensus statement on the treatment of paediatric arrhythmias has been released by the European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC) and the Association for European Paediatric and Congenital Cardiology (AEPC). “Pharmacological and non-pharmacological therapy for arrhythmias in the paediatric population” was published in EP-Europace.1 Consensus statements

Chest radiation cancer patients with risk factors should have CV screening every 5-10 years

Radiation-induced heart disease increasingSophia Antipolis, 16 July 2013: Cancer patients who receive chest radiation should be screened for heart disease every 5-10 years, according to the European Association of Cardiovascular Imaging (EACVI) of the European Society of Cardiology (ESC) and the American Society of Echocardiography (ASE). Their recommendations are outlined in the first expert consensus statement on screening for radiation-induced heart disease (RIHD), published today in European Heart Journal – Cardiovascular Imaging.1 Professor Patrizio Lancellotti, chair of the

2013 ESH/ESC Guidelines for the management of arterial hypertension

Landmark clinical Guidelines introduced at Europe’s biggest blood pressure conference in MilanEmbargo, 17.30 (CEST) Friday 14th June, 2013 Milan, 14 June 2013. Lifestyle factors, lack of awareness by both patients and physicians, hesitancy in initiating and intensifying drug treatment, and healthcare structural deficiencies are amongst the reasons for the increasing problem of high blood pressure in Europe, according to new joint Guidelines issued today by the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). The Guidelines, which recommend several

Swedish registry questions superiority of bivalirudin over heparin in patients undergoing PCI for NSTE-ACS

21 May 2013, Paris, France: Results from a large observational study reported at EuroPCR 2013 today question whether bivalirudin is superior to heparin in the absence of GPIIb/IIIa blockade, showing similar 30-day mortality in patients with non-ST segment elevation acute coronary syndromes (NSTE-ACS) undergoing percutaneous coronary intervention (PCI). European and US NSTE-ACS guidelines currently recommend bivalirudin alone as an alternative to unfractionated heparin plus GP IIb/IIIa receptor inhibitors in patients undergoing an intended urgent or early invasive strategy. Researchers

First results from DESolve Nx trial show low rate of late lumen loss with bioresorbable DESolve device

21 May 2013, Paris, France: The DESolve bioresorbable coronary scaffold system achieves good efficacy and safety with low rates of late lumen loss and major coronary adverse events at six months, show first results from the pivotal DESolve Nx trial reported at EuroPCR 2013 today. DESolve (Elixir Medical Corporation) is the first bioresorbable PLLA-based polymer scaffold that releases novolimus, a major metabolite of sirolimus. “The degradation time is about one year,” explained the lead study author Alexandre Abizaid, Director of Interventional Cardiology at Institute Dante Pazzanese de

Biodegradable Orsiro stent proves non-inferior to Xience Prime drug-eluting stent for in-stent late lumen loss at nine months

21 May 2013, Paris, France: The Orsiro stent, which is a novel stent platform eluting sirolimus from a biodegradable polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting stent for the primary angiographic endpoint of in-stent late lumen loss at nine months in the results of an imaging substudy reported at EuroPCR 2013 today. The BIOFLOW-II substudy used intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to quantitatively assess neointimal hyperplasia and stent apposition at nine months after treating patients with symptomatic coronary artery

Post-approval TAVI registry shows high rates of device success at one year

One-year results from SOURCE XT – one of the largest, post-approval transcatheter aortic valve implantation (TAVI) registries21 May 2013, Paris, France: One-year results from SOURCE XT – one of the largest, post-approval transcatheter aortic valve implantation (TAVI) registries to-date – reported today at EuroPCR 2013 show good clinical outcomes in routine clinical practice, with high rates of device success for all access approaches, valve sizes and delivery systems. The SOURCE XT Post-Approval Study followed up 2688 consecutively enrolled patients (mean age 81.5 years) undergoing TAVI

ESC responds to European Commission Proposals for new regulation to govern medical devices

The priority must be to ensure patient safetySophia Antipolis, 8 March 2013. In a position paper¹, the European Society of Cardiology (ESC) welcomes the European Commission’s (EC’s) proposals for a new Regulation to govern the evaluation and approval of medical devices in Europe² as an important step towards improving patient safety. The position paper, coordinated by the ESC Task Force on Medical Devices, comes as the European Commission proposal is being considered by The European Parliament and The Council of the European Union. The ESC authors have outlined five further suggestions

European Society of Cardiology Opens Brussels Bureau

• Science is not enough to stop the cardiovascular disease epidemic• Fifty percent of CVD deaths could be prevented with proper policies• In light of growing CVD burden, policy needs to focus on primary prevention Brussels, 27 February 2013. While the treatment of heart diseases in both primary and hospital care has been very successful with mortality rates declining markedly over the past 20 years, at the community level the primary prevention of cardiovascular disease (CVD), despite the notable

Deprivation plays an important role in CVD, but interventions are not developed towards people from lower socio-economic groups

EuroHeartCare congress takes place 22 March – 23 March 2013, at the Scottish Exhibition and Conference Centre (SECC) Glasgow, UKEuroHeartCare congress takes place 22 March – 23 March 2013, at the Scottish Exhibition and Conference Centre (SECC) Glasgow, UK · Allied Health Professions at the heart of cardiovascular care · Nurses undertake ever more specialized roles in cardiovascular treatment At the opening of the EuroHeartCare congress, the annual meeting of the European Society of Cardiology (ESC’s) Council of Cardiovascular Nursing and Allied Health Professions (CCNAP), a

Creeping epidemic of obesity hits Asia Pacific region

· Overnutrition replaces undernutrition · Overweight and obesity quadruples in China · 80% of all cardiovascular disease is preventable and policies should be encouraged to make healthy choices easySophia Antipolis, 21 February 2013: Over eating, sedentary lifestyles, cultural attitudes, and lack of prevention programmes are to blame for the rising epidemic of obesity in the Asia Pacific region. Overweight and obesity has quadrupled in China and societies still label people of healthy weight as poor. Prevention will be an important theme at the 19th Asian Pacific Congress of

ESC responds to EU Clinical trials directive revisions

Embargo: Wednesday 13 February 01:30am CET Sophia Antipolis, 13 February 2013. In anticipation of the consideration of the draft report by the European Parliament Environment, Public Health and Food Safety (ENVI) Committee expected early next week, a position paper¹ by the European Society of Cardiology (ESC) welcomes the “spirit” of the European Commission’s proposed revision of the text of the European Clinical Trials Directive (EUCTD) ², as an important contribution to “simplifying, clarifying and streamlining” rules for conducting clinical trials across Europe. The position paper,

CVD time bomb set to explode in Gulf region in 10-15 years

More than one-third are obese and one-quarter have diabetesEmbargo: 13 February 2013 00:30 CET Sophia Antipolis, 13 February 2013: With one of the highest rates of obesity in the world, the Gulf region is facing an epidemic of cardiovascular disease. At least 50% of the population is below the age of 25 and the high prevalence of risk factors signals a massive wave of cardiovascular disease in 10-15 years. Cardiovascular centres are already bursting at the seams and prevention services are nonexistent. Prevention will be a key theme at the Saudi Heart Association annual conference,

There are no items matching the current filter
There are no more items matching the current filter
Back to top